Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-pragmatic research and innovation through multinational experimentation.

Omerovic, E. et al. (2024) Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-pragmatic research and innovation through multinational experimentation. Trials, 25, 80. (doi: 10.1186/s13063-024-07935-y) (PMID:38263138) (PMCID:PMC10807265)

Abstract

In an era focused on value-based healthcare, the quality of healthcare and resource allocation should be underpinned by empirical evidence. Pragmatic clinical trials (pRCTs) are essential in this endeavor, providing randomized controlled trial (RCT) insights that encapsulate real-world effects of interventions. The rising popularity of pRCTs can be attributed to their ability to mirror real-world practices, accommodate larger sample sizes, and provide cost advantages over traditional RCTs. By harmonizing efficacy with effectiveness, pRCTs assist decision-makers in prioritizing interventions that have a substantial public health impact and align with the tenets of value-based health care. An international network for pRCT provides several advantages, including larger and diverse patient populations, access to a broader range of healthcare settings, sharing knowledge and expertise, and overcoming ethical and regulatory barriers. The hypothesis and study design of pRCT answers the decision-maker's questions. pRCT compares clinically relevant alternative interventions, recruits participants from diverse practice settings, and collects data on various health outcomes. They are scarce because the medical products industry typically does not fund pRCT. Prioritizing these studies by expanding the infrastructure to conduct clinical research within the healthcare delivery system and increasing public and private funding for these studies will be necessary to facilitate pRCTs. These changes require more clinical and health policy decision-makers in clinical research priority setting, infrastructure development, and funding. This paper presents a comprehensive overview of pRCTs, emphasizing their importance in evidence-based medicine and the advantages of an international collaborative network for their execution. It details the development of PRIME-9, an international initiative across nine countries to advance pRCTs, and explores various statistical approaches for these trials. The paper underscores the need to overcome current challenges, such as funding limitations and infrastructural constraints, to leverage the full potential of pRCTs in optimizing healthcare quality and resource utilization.

• Item Type: Articles
• Keywords: Humans, Sample Size, Evidence-Based Medicine, Research Design, Administrative Personnel, Randomized Controlled Trials as Topic
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Petrie, Professor Mark
• Authors: Omerovic, E., Petrie, M., Redfors, B., Fremes, S., Murphy, G., Marquis-Gravel, G., Lansky, A., Velazquez, E., Perera, D., Reid, C., Smith, J., van der Meer, P., Lipsic, E., Juni, P., McMurray, J., Bauersachs, J., Køber, L., Rouleau, J. L., and Doenst, T.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Trials
• Publisher: BioMed Central
• ISSN: 1745-6215
• ISSN (Online): 1745-6215
• Copyright Holders: Copyright: © The Author(s) 2024
• First Published: First published in Trials 25: 80
• Publisher Policy: Reproduced under a Creative Commons licence